Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler will be retiring, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio.

Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer

RED BANK, N.J., Nov. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

RED BANK, N.J., Oct. 28, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2021 financial results on Thursday, November 4, 2021, before the opening of the U.S. financial markets.

Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

Provention Bio Inc (NASDAQ: PRVB) has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all five key CVB strains associated with type 1 diabetes (T1D) autoimmunity.

Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate

RED BANK, N.J., Oct. 26, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive interim results from PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all five key CVB strains associated with type 1 diabetes (T1D) autoimmunity.

Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on Wednesday, September 29, 2021 at 3:20 pm E.T.

Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021

RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 22, 2021 at 9:05 am E.T.

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021.

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission

Atea Pharmaceuticals

Histogen

NeuroBo Pharmaceuticals Inc

InVivo Therapeutics

Synthetic Biologics

Seqll

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2021 Results - Earnings Call Transcript

RED BANK, N.J., Aug. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

It's been almost 18 months since I posted a comprehensive clinical overview of Provention Bio's main molecule teplizumab.

Provention Bio: Blood (Glucose) In The Streets

RED BANK, N.J., July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2021 financial results on Thursday, August 5, 2021, before the opening of the U.S. financial markets.

Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021

New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of...

PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB

Los Angeles, California--(Newsfile Corp. - July 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - July 19, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB

New York, New York--(Newsfile Corp. - July 19, 2021) - WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline.SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of...

PRVB TUESDAY DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pr

PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021

Los Angeles, California--(Newsfile Corp. - July 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its officers.   The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB

NEW YORK, July 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021, inclusive (the "Class Period"), of the important July 20, 2021 lead plaintiff deadline. SO WHAT: If you purchased Provention Bio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

FINAL DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - PRVB

New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB).Shareholders who purchased shares of PRVB during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/provention-bio-inc-loss-submission-form/?id=17728&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - (PRVB)

New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc. ("Provention Bio") (NASDAQ: PRVB) between November 2, 2020 and April 8, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.

PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $PRVB #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)

Los Angeles, California--(Newsfile Corp. - July 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. ("Provention" or "the Company") (NASDAQ: PRVB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 2, 2020 and April 8, 2021, inclusive...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

News for Provention Bio Inc Stock (PRVB)